等待開盤 03-26 09:30:00 美东时间
-0.071
-9.35%
今日重点评级关注:HC Wainwright & Co.:维持OCUGEN"买入"评级,目标价从7美元升至10美元;HC Wainwright & Co.:维持Maze Therapeutics"买入"评级,目标价从60美元升至110美元
今天 11:41
TELA Bio (NASDAQ:TELA) reported mixed Q4 results, with higher losses but lower sales than expected. Analysts lowered price targets for the stock.
今天 04:37
Top analysts change outlook for top names. Citigroup, Tigress Fin, Piper Sandler, Morgan Stanley, HC Wainwright, Susquehanna, Raymond James and Goldman Sachs adjust price targets for companies like Braze, Amazon, TELA Bio, Smithfield Foods, Corcept Therapeutics, TechnipFMC, Phillips 66, and KB Home. See all changes at benzinga.com/analyst-stock-ratings.
今天 04:11
Canaccord Genuity analyst Caitlin Roberts maintains TELA Bio (NASDAQ:TELA) with a Buy and lowers the price target from $4 to $2.
03-25 22:00
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据TELA Bio业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 2025年第四季度营收2,090万美元,同比增长18% - 2025年全年营收8,030万美元,同比增长16% - OviTex产品全年增长12%,OviTex PRS产品全年增长20% - LiquiFix产品营收较上年增长超过两倍 - 欧洲销售占总营收15%,达1,210万美元,同比增长17% **盈利能力:** - 第四季度毛利率66%,全年毛利率68%,较上年同期的64%和67%有所改善 - 运营亏损:第四季度660万美元,全年3,380万
03-25 12:04
TELA Bio (NASDAQ:TELA) FY2026 Revenue expected to be more than $86.697M vs $92.674M Est
03-25 04:17
TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 26.09 percent increase over losses of $(0.23) per share from the same
03-25 04:15
Companies Reporting Before The Bell • Fennec Pharmaceuticals (NASDAQ:FENC) is e...
03-24 19:11
NotificationCenter TELA Bio, Inc. announced it will report its fourth quarter and full year 2025 financial results on March 24, 2026. The company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
03-10 20:05
TELA Bio Grants Restricted Stock Units to New Employees TELA Bio Inc. has announced that its Compensation Committee has approved inducement grants of restricted stock units covering 14,250 shares of common stock to five newly hired employees. These restricted stock units will vest in equal annual in
01-26 15:26